Significance of serum CD44V6 and VEGF in diagnosis of colorectal cancer liver metastasis in rats

doi:10.3877/cma.j.issn.2095-3232.2017.03.018

Abstract

Abstract:

Objective

To investigate the significance of serum CD44V6 and VEGF in the diagnosis of colorectal cancer liver metastasis (CLM) in rats.

Methods

Seventy-two healthy female SD rats with the weight of 320-360 g and the age of 20 weeks were divided into the CLM group (n=54) and control group (n=18) according to the nonreplacement sampling method. CLM rat models were successfully established by continuously subcutaneous injection of dimethyl hydrazine in the CLM group. The animals in two groups were respectively sacrificed at 13, 17 and 21 weeks. The size and quantity of metastatic liver tumors were recorded. The expression of serum CD44V6 and VEGF at different time points were dynamically detected by ELISA. The pathological types of colorectal tumors and metastatic liver tumors were observed by HE staining. The status of the rats throughout the experimental process was observed in two groups. Pathological findings and serum CD44V6 and VEGF levels were compared between two groups. The positive expression of serum CD44V6 and VEGF in the CLM group was observed. The experimental data between two groups were compared by t test, and were compared by one-way analysis of variance and LSD-t test between three groups.

Results

As the experiment time went on, the quantity and diameter of metastatic liver tumors in the CLM group gradually increased (F=22.78, 33.86; P<0.05). No tumor or polyp was observed in the colon, rectum and liver in the control group. As the experiment time went on, the serum CD44V6 and VEGF levels were gradually up-regulated (F=12.35, 18.26; P<0.05). The serum CD44V6 levels at 13, 17 and 21 weeks and the serum VEGF levels at 17 and 21 weeks were respectively (15±5), (19±6), (36±4) μg/L and (106±6), (195±22) ng/L in the CLM group, significantly higher than (10±3), (11±4), (12±3) μg/L and (76±18), (75±18) ng/L in the control group (t=2.12, 2.50, 2.96 and 2.38, 3.49; P<0.05). As the experiment time went on, the positive rates of serum CD44V6 and VEGF in the CLM group were gradually enhanced. When two indexes were combined detected, the positive rate of either index was higher than that of any single index. At 21 weeks, the positive rates of two indexes reached 100%.

Conclusions

Along with the progression of the disease, the serum CD44V6 and VEGF levels of the rats in the CLM group are gradually up-regulated. Combined detection of serum CD44V6 and VEGF may probably contribute to early diagnosis of CLM.

Key words: CD44V6, Vascular endothelial growth factors, Colonic neoplasms, Neoplasm metastasis, Liver, Rats

Xiangqiong Mo, Bin Niu, Juyuan Bu, Baojun Lyu, Bingzong Hou. Significance of serum CD44V6 and VEGF in diagnosis of colorectal cancer liver metastasis in rats[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2017, 06(03): 233-237.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2017.03.018

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2017/V06/I03/233

Figures/Tables 4

References 18

[1]	杨扬，汪国营．结直肠癌肝转移的治疗策略[J/CD]．中华肝脏外科手术学电子杂志，2015，4(1):1-5.
[2]	Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making[J]. Ann Oncol, 2012, 23(10):2479-2516．
[3]	Bourguignon LY, Wong G, Earle C, et al. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma[J]. J Biol Chem, 2012, 287(39):32800-32824.
[4]	Chen Y, Fu Z, Xu S, et al. The prognostic value of CD44 expression in gastric cancer: a meta-analysis[J]. Biomed Pharmacother, 2014, 68(6):693-697.
[5]	谢建伟，黄昌明，郑朝辉，等．肿瘤干细胞表面标记物CD44在胃癌中的表达及其意义[J]．中华胃肠外科杂志，2013，16(11):1107-1112.
[6]	刘琪，左文述，王新昭，等．乳腺癌原发灶和淋巴结转移灶激素受体及HER-2与Ki-67表达相关性分析[J]．中华肿瘤防治杂志，2013，20(15): 1153-1157.
[7]	Heider KH, Kiefer K, Zenz T, et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies[J]. Blood, 2011, 118(15):4159-4168.
[8]	陈仕才，宋新明，陈志辉，等．CD133和CD44在结直肠癌细胞中的表达及其与患者5年生存率的相关性分析[J]．中国病理生理杂志，2011，27(5):883-889.
[9]	Gurtner K, Hessel F, Eicheler W, et al. Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo[J]. Radiother Oncol, 2012, 102(3):444-449.
[10]	Krause G, Patz M, Isaeva P, et al. Action of novel CD37 antibodies on chronic lymphocytic leukemia cells[J]. Leukemia, 2012, 26(3):546-549.
[11]	郭庆喜，蒲霞，王玺皓，等．结直肠癌组织中CD44V6、MMP-7和E-cadherin表达及临床意义[J]．现代预防医学，2013，40(23):4478-4481.
[12]	刘婷婷，刘溪，胡江峰，等．结肠癌患者血清中miRNA-21含量检测及其与VEGF水平的关系研究[J]．海南医学院学报，2014，20(11): 1533-1535.
[13]	Malhot L, Stenninger J. Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding[J]. Cancer Sci, 2012, 103(4): 626-631.
[14]	Tie J, Desai J. Antiangiogenic threapies targeting the vascular endothelia growth factor signaling system[J]. Crit Rev Oncog, 2012, 17(1):51-67.
[15]	Eichmann A, Simons M. VEGF signaling inside vascular endothelial cells and beyond[J]. Curr Opin Cell Biol, 2012, 24(2): 188-193.
[16]	阮森林，王晓磊，施新颜．结直肠癌患者手术前后血清CRP、CEA和VEGF检测的临床意义[J]．浙江中西医结合杂志，2012，22(12):935-937.
[17]	徐卫国，王宇鹏，孙红，等．大肠癌组织中NRP-2、NRP-1的表达及其与肿瘤淋巴结转移的相关性研究[J]．重庆医学，2013，42(4): 382-384,387.
[18]	Hamdollah Zadeh MA, Amin EM, Hoareau-Aveilla C, et al. Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance[J]. Mol Oncol, 2015, 9(1):167-178.

周数	鼠数（只）	CLM发生率（%）	肝转移瘤数（个/只，±s）	转移瘤直径（mm，±s）	腹腔积液
13周	18	11	1.2±0.3	1.42±0.10	无
17周	18	50	3.2±1.3	4.10±0.82	无
21周	15	100	7.3±3.2	6.22±3.86	7.6 ml，血性

周数	鼠数（只）	CLM发生率（%）	肝转移瘤数（个/只，±s）	转移瘤直径（mm，±s）	腹腔积液
13周	18	11	1.2±0.3	1.42±0.10	无
17周	18	50	3.2±1.3	4.10±0.82	无
21周	15	100	7.3±3.2	6.22±3.86	7.6 ml，血性

组别	鼠数（只）	13周		17周		21周^a
组别	鼠数（只）	CD44V6（μg/L）	VEGF（ng/L）	CD44V6（μg/L）	VEGF（ng/L）	CD44V6（μg/L）	VEGF（ng/L）
CLM组	18	15±5	88±21	19±6	106±16	36±4	195±22
对照组	06	10±3	70±17	11±4	076±18	12±3	075±18
t	?	2.12	2.07	2.50	2.38	2.96	3.49
P	?	<0.05	>0.05	<0.05	<0.05	<0.05	<0.05

组别	鼠数（只）	13周		17周		21周^a
组别	鼠数（只）	CD44V6（μg/L）	VEGF（ng/L）	CD44V6（μg/L）	VEGF（ng/L）	CD44V6（μg/L）	VEGF（ng/L）
CLM组	18	15±5	88±21	19±6	106±16	36±4	195±22
对照组	06	10±3	70±17	11±4	076±18	12±3	075±18
t	?	2.12	2.07	2.50	2.38	2.96	3.49
P	?	<0.05	>0.05	<0.05	<0.05	<0.05	<0.05

时间	鼠数（只）	CD44V6阳性率	VEGF阳性率	任一项阳性百分率
13周	18	044%（8/18）	039%（7/18）	061%（11/18）
17周	18	078%（14/18）	072%（13/18）	094%（17/18）
21周	15	100%（15/15）	100%（15/15）	100%（15/15）

Please choose a citation manager

Content to export